- Home
- ITRM vs ALGS Comparison
ITRM vs ALGS Comparison
Compare ITRM & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRM
- ALGS
- Stock Information
- Founded
- ITRM 2015
- ALGS 2018
- Country
- ITRM Ireland
- ALGS United States
- Employees
- ITRM N/A
- ALGS N/A
- Industry
- ITRM Biotechnology: Pharmaceutical Preparations
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- ITRM Health Care
- ALGS Health Care
- Exchange
- ITRM Nasdaq
- ALGS Nasdaq
- Market Cap
- ITRM 40.0M
- ALGS 36.0M
- IPO Year
- ITRM 2018
- ALGS 2020
- Fundamental
- Price
- ITRM $1.01
- ALGS $7.21
- Analyst Decision
- ITRM Strong Buy
- ALGS Strong Buy
- Analyst Count
- ITRM 2
- ALGS 1
- Target Price
- ITRM $7.00
- ALGS $70.00
- AVG Volume (30 Days)
- ITRM 481.0K
- ALGS 134.1K
- Earning Date
- ITRM 08-13-2025
- ALGS 08-05-2025
- Dividend Yield
- ITRM N/A
- ALGS N/A
- EPS Growth
- ITRM N/A
- ALGS N/A
- EPS
- ITRM N/A
- ALGS N/A
- Revenue
- ITRM N/A
- ALGS $3,270,000.00
- Revenue This Year
- ITRM N/A
- ALGS N/A
- Revenue Next Year
- ITRM $270.19
- ALGS $51.55
- P/E Ratio
- ITRM N/A
- ALGS N/A
- Revenue Growth
- ITRM N/A
- ALGS N/A
- 52 Week Low
- ITRM $0.81
- ALGS $3.76
- 52 Week High
- ITRM $3.02
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- ITRM 51.14
- ALGS 51.55
- Support Level
- ITRM $0.93
- ALGS $7.11
- Resistance Level
- ITRM $1.06
- ALGS $8.66
- Average True Range (ATR)
- ITRM 0.05
- ALGS 0.83
- MACD
- ITRM 0.01
- ALGS -0.05
- Stochastic Oscillator
- ITRM 34.78
- ALGS 18.59
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.